www.fdanews.com/articles/193158-solasia-pharmas-episil-pain-relief-device-approved-in-korea
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
Solasia Pharma’s Episil Pain Relief Device Approved in Korea
October 21, 2019
South Korea’s National Institute of Medical Device Safety Information has approved Solasia Pharma’s pain relief device, a product that delivers episil oral liquid for creating a protective film over oral wounds.
The pocket-sized medical device is indicated for managing and relieving oral cavity pain resulting from chemotherapy or radiotherapy. The device has already been cleared in the U.S., the EU, Japan and China.
According to clinical results, episil quickly provides oral pain relief and physical protection that lasts up to eight hours.